Active Equities to Watch in the Healthcare Sector -- AstraZeneca, Valeant Pharma, Novartis, Heron Therapeutics and Alkermes

Aug 10, 2015, 09:15 ET from www.equityresearchinstitute.com

NEW YORK, August 10, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: AstraZeneca PLC (NYSE: AZN), Valeant Pharmaceuticals International Inc. (NYSE: VRX), Novartis A.G. (NYSE: NVS), Heron Therapeutics Inc. (NASDAQ: HRTX) and Alkermes PLC (NASDAQ: ALKS). Free research report on AstraZeneca can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AZN. On Friday, August 07, 2015, the NASDAQ Composite ended at 5,043.54, down 0.26%, the Dow Jones Industrial Average lost 0.27%, to finish the day at 17,373.38 and the S&P 500 closed at 2,077.57, down 0.29%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.  

AstraZeneca PLC's stock lost 1.61%, to close the day at $33.69. The stock recorded a trading volume of 3.27 million shares, above its three months average volume of 2.67 million shares. Over the past three months and since the start of this year, AstraZeneca PLC's shares have fallen by 3.63% and 1.58%, respectively. However, the stock has advanced 4.38% in the last one month. The company's shares are trading 1.21% above their 50-day moving average. Additionally, AstraZeneca PLC traded at a PE ratio of 71.68 and has a Relative Strength Index (RSI) of 52.01. Sign up and read the free notes on AZN at:

https://www.EquityResearchInstitute.com/reports?keyword=AZN

On Friday, shares in Valeant Pharmaceuticals International Inc. recorded a trading volume of 2.15 million shares, higher than their three months average volume of 1.62 million shares. The stock ended the day 0.25% lower at $247.79. Shares of the company traded at a PE ratio of 101.97. Valeant Pharmaceuticals International Inc.'s stock has surged 10.92% in the last one month, 11.68% in the previous three months and 73.15% on YTD basis. The company is trading above its 50-day and 200-day moving averages by 4.26% and 30.45%, respectively. Furthermore, shares of Valeant Pharmaceuticals International Inc. have an RSI of 52.10. The complimentary notes on VRX can be downloaded in PDF format at:

https://www.EquityResearchInstitute.com/reports?keyword=VRX

Novartis AG's stock edged 0.12% lower, to close Friday's session at $102.21. The stock recorded a trading volume of 1.08 million shares, below its three months average volume of 1.59 million shares. Over the last one month and since the beginning of 2015, Novartis AG's shares have advanced 2.19% and 13.43%, respectively. However, the stock has lost 0.69% in the previous three months. The company is trading 0.06% and 4.33% above its 50-day and 200-day moving averages, respectively. Furthermore, Novartis AG's stock traded at a PE ratio of 25.88 and has an RSI of 47.09. Register for free on Equity Research Institute and access the latest research on NVS at:

https://www.EquityResearchInstitute.com/reports?keyword=NVS

Heron Therapeutics Inc.'s stock finished Friday's session 0.67% higher at $31.58. A total of 0.70 million shares were traded, which was below its three months average volume of 1.50 million shares. Over the last one month and the previous three months, Heron Therapeutics Inc.'s shares have surged 4.71% and 157.59%, respectively. Additionally, the stock has rallied 213.92% since the beginning of 2015. The company's shares are trading above their 50-day and 200-day moving averages by 3.98% and 101.55%, respectively. Heron Therapeutics Inc.'s stock has an RSI of 47.65. The complete research on HRTX is available for free at:

https://www.EquityResearchInstitute.com/reports?keyword=HRTX

On Friday, shares in Alkermes PLC ended the session 0.80% lower at $67.21. The stock reported a trading volume of 0.82 million shares, below its three months average volume of 0.96 million shares. Alkermes PLC's shares have gained 7.81% in the last one month, 13.43% in the previous three months and 14.77% on YTD basis. The company is trading 3.41% above its 50-day moving average and 7.95% above its 200-day moving average. Moreover, shares of Alkermes PLC have an RSI of 50.41. Free in-depth research on ALKS is available at:

https://www.EquityResearchInstitute.com/reports?keyword=ALKS

--

About Equity Research Institute: 

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.equityresearchinstitute.com.

RESTRICTIONS 

ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.equityresearchinstitute.com